- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05932238
Systane® Hydration PF and Systane® Hydration Preserved
April 9, 2024 updated by: Alcon Research
The purpose of this post-market clinical follow-up (PMCF) study is to assess the performance and safety of Systane Hydration Preservative Free (PF) in subjects experiencing dry eye symptoms (Group 1) and in contact lens (CL) wearers experiencing discomfort due to CL-related dryness (Group 2) and also Systane Hydration Preserved in CL wearers experiencing discomfort due to CL-related dryness (Group 3).
Statistical analyses will be presented by group.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Subjects will participate in the study for approximately 30 days, with a phone call scheduled on Day 15 ± 2 (Visit 2) and a follow-up visit scheduled on Day 30 ± 2 (Visit 3).
Subjects will be asked to complete patient questionnaires on Day 1 and at Visit 3 (Impact of Dry Eye on Everyday Life - Symptom Bother [IDEEL-SB] or Contact Lens Dry Eye Questionnaire [CLDEQ-8] and Comfortable Wear Time questions).
Study Type
Interventional
Enrollment (Estimated)
135
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alcon Call Center
- Phone Number: 1-888-451-3937
- Email: alcon.medinfo@alcon.com
Study Locations
-
-
British Columbia
-
Burnaby, British Columbia, Canada, V5E 1G3
- Recruiting
- Integra Eye Care
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
- Recruiting
- Aggarwal and Associates Limited
-
Waterloo, Ontario, Canada, N2L 3G1
- Recruiting
- University of Waterloo School of Optometry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject must be able to understand and sign an informed consent form
- Subject with mild to moderate dry eye
- Subject with CL-related dry eye symptoms
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- Has suffered any ocular injury to either eye in the past 3 months prior to screening.
- Has undergone any other ocular surgery (including intraocular surgery) within the past 6 months or has any ocular surgery planned during the study.
- Other protocol-defined exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systane Hydration Preservative Free (PF)
1-2 drops in each eye four times a day for 30 days
|
commercially available eye drops
Other Names:
|
Experimental: Systane Hydration Preserved
1-2 drops in each eye four times a day for 30 days
|
commercially available eye drops
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean overall IDEEL-Symptom Bother(SB) score - Group 1
Time Frame: Visit 3 (Day 30)
|
The IDEEL-SB (Version 1) symptom bother module consists of 20 questions that assess general dry eye symptoms a subject experiences.
The subject will be instructed to select a single response that best represents their answer.
The Symptom Bother score is calculated as the mean value of the non-missing item scores 1-20 multiplied by 25.
No statistical hypothesis is pre-specified for this endpoint.
|
Visit 3 (Day 30)
|
Resultant overall CLDEQ-8 score - Group 2 and Group 3
Time Frame: Visit 3 (Day 30)
|
The CLDEQ-8 is an eight-item questionnaire that evaluates the severity of dry eye symptoms in soft contact lens wearers within the past 2 weeks.
Each question is answered using a 0-4, 0-5, or 1-6 Likert scale for a resultant overall score of 1-37.
No statistical hypothesis is pre-specified for this endpoint.
|
Visit 3 (Day 30)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Lead, Vision Care, Alcon Research, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 6, 2023
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
June 27, 2023
First Submitted That Met QC Criteria
June 27, 2023
First Posted (Actual)
July 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DEN923-I001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)
-
TecnoquimicasRecruitingDry Eye DiseaseColombia
-
Laboratorios Sophia S.A de C.V.Completed
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Laboratorios Sophia S.A de C.V.CompletedDry Eye Syndromes | Lubricant Allergy | Tear DisorderMexico
-
Calm Water Therapeutics LLCAndover Research Eye InstituteCompletedDry Eye DiseaseUnited States
-
University of FaisalabadNot yet recruiting
-
Calm Water Therapeutics LLCCompletedKeratoconjunctivitis SiccaUnited States